Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cellgram CKD

Next Previous
X
Search
Drug Profile

Cellgram CKD

Alternative Names: Allogeneic bone marrow-derived mesenchymal stem cell therapy; Cellgram-CKD; Cellgram_CKD

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmicell
  • Developer Asan Medical Center; Pharmicell
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Angiogenesis modulating agents; Apoptosis inhibitors; Cell replacements; Immunogenetic modulators; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Renal failure

Most Recent Events

  • 01 Nov 2021 Pharmicell plans a long-term follow-up study for Renal failure in South Korea (IV) (NCT05096182)
  • 16 Sep 2021 Phase I clinical trials in Renal failure in South Korea (IV) (NCT05042206) (Pharmicell pipeline, September 2021)
  • 25 Jul 2021 Ministry of Food and Drug Safety of Korea approves IND application for Cellgram CKD in Renal failure (Pharmicell pipeline, September 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top